Afinitor and Paranasal sinus hypersecretion - a phase IV clinical study of FDA data
Paranasal sinus hypersecretion is found among people who take Afinitor, especially for people who are female, 40-49 old, have been taking the drug for 6 - 12 months.
The phase IV clinical study analyzes which people take Afinitor and have Paranasal sinus hypersecretion. It is created by eHealthMe based on reports of 39,807 people who have side effects when taking Afinitor from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
39,807 people reported to have side effects when taking Afinitor.
Among them, 6 people (0.02%) have Paranasal sinus hypersecretion.
What is Afinitor?
Afinitor has active ingredients of everolimus. It is often used in breast cancer metastatic. eHealthMe is studying from 39,878 Afinitor users for its effectiveness, alternative drugs and more.
What is Paranasal sinus hypersecretion?
Paranasal sinus hypersecretion is found to be associated with 698 drugs and 386 conditions by eHealthMe.
Number of Afinitor and Paranasal sinus hypersecretion reports submitted per year:
Time on Afinitor when people have Paranasal sinus hypersecretion *:
- < 1 month: 0.0 %
- 1 - 6 months: 50 %
- 6 - 12 months: 50 %
- 1 - 2 years: 0.0 %
- 2 - 5 years: 0.0 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
Gender of people who have Paranasal sinus hypersecretion when taking Afinitor *:
- female: 83.33 %
- male: 16.67 %
Age of people who have Paranasal sinus hypersecretion when taking Afinitor *:
- 0-1: 0.0 %
- 2-9: 20 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 60 %
- 50-59: 0.0 %
- 60+: 20 %
Common drugs people take besides Afinitor *:
- Vitamin B12: 2 people, 33.33%
- Vyvanse: 1 person, 16.67%
- Aromasin: 1 person, 16.67%
- Atenolol: 1 person, 16.67%
- Carafate: 1 person, 16.67%
- Concerta: 1 person, 16.67%
- Cozaar: 1 person, 16.67%
- Exemestane: 1 person, 16.67%
- Glipizide: 1 person, 16.67%
- Glucotrol: 1 person, 16.67%
Common side effects people have besides Paranasal sinus hypersecretion *:
- Joint Pain: 3 people, 50.00%
- Weight Decreased: 3 people, 50.00%
- Fever: 3 people, 50.00%
- Stomatitis (inflammation of mucous membrane of mouth): 3 people, 50.00%
- Sinusitis (inflammation of sinus): 3 people, 50.00%
- Oropharyngeal Pain: 3 people, 50.00%
- Hot Flush (sudden feelings of heat): 3 people, 50.00%
- White Blood Cell Count Decreased: 2 people, 33.33%
- Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 2 people, 33.33%
- Nausea And Vomiting: 2 people, 33.33%
Common conditions people have *:
- Angiomyolipoma (most common benign tumour of the kidney): 3 people, 50.00%
- Vitamin B12 Decreased: 2 people, 33.33%
- High Blood Pressure: 2 people, 33.33%
- Benign Renal Neoplasm (benign (non-cancerous) tumours of the kidney): 2 people, 33.33%
- Diabetes: 1 person, 16.67%
- Astrocytoma, Low Grade (low grade tumour of the brain that originate in a particular kind of glial-cells): 1 person, 16.67%
* Approximation only. Some reports may have incomplete information.
Do you take Afinitor and have Paranasal sinus hypersecretion?Check whether Paranasal sinus hypersecretion is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
How severe was Paranasal sinus hypersecretion and when was it recovered:
Expand to all the drugs that have ingredients of everolimus:
Alternative drugs to, pros and cons of Afinitor:
- Afinitor (39,878 reports)
Common Afinitor side effects:
Browse all side effects of Afinitor:a b c d e f g h i j k l m n o p q r s t u v w x y z
Paranasal sinus hypersecretion treatments and more:
- Paranasal sinus hypersecretion (4,043 reports)
COVID vaccines that are related to Paranasal sinus hypersecretion:
- Paranasal sinus hypersecretion in Moderna COVID Vaccine
- Paranasal sinus hypersecretion in Pfizer BioNTech Covid Vaccine
- Paranasal sinus hypersecretion in Johnson and Johnson Covid Vaccine
Common drugs associated with Paranasal sinus hypersecretion:
All the drugs that are associated with Paranasal sinus hypersecretion:
- Paranasal sinus hypersecretion (698 drugs)
Common conditions associated with Paranasal sinus hypersecretion:
All the conditions that are associated with Paranasal sinus hypersecretion:
- Paranasal sinus hypersecretion (386 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on everolimus (the active ingredients of Afinitor) and Afinitor (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Duloxetine Hydrochloride and Cardio-Respiratory Arrest - 2 seconds ago
- Prednisolone and Eczema Nummular - 5 seconds ago
- Sandostatin Lar and Diabetes Mellitus Inadequate Control - 9 seconds ago
- Hydroxychloroquine Sulfate and Ubrelvy drug interaction - 10 seconds ago
- Methadone Hydrochloride and Musculoskeletal Discomfort - 15 seconds ago
- Profen and Trilyte drug interaction - 15 seconds ago
- Xeloda and Dry Eye Syndrome - 16 seconds ago
- Pravachol and Didanosine drug interaction - 18 seconds ago
- Enalapril Maleate and Ventricular Fibrillation - 20 seconds ago
- Spiriva and Pulmonary Mass - 22 seconds ago